Between the Biotech Waves
Episode 8 John Leonard CEO of Intellia Therapeutics
Jun 21, 2022
John Leonard, CEO of Intellia Therapeutics, boasts over 30 years in drug research and development. He discusses Intellia's inception and the challenges faced during the launch of genome editing programs. Insights into the ethical concerns surrounding biotechnology are explored, with a focus on gene editing implications. Leonard also reflects on the competitive landscape of the CRISPR sector and emphasizes the importance of making genetic therapies accessible and affordable for patients. His experiences and commitment highlight the evolving landscape of biotech.
49:54
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- John Leonard reflects on how his experiences during the AIDS epidemic shaped his commitment to developing impactful therapeutic options for patients.
- The strategic use of lipid nanoparticles in Intellia's treatments exemplifies their innovative approach to efficiently delivering genetic therapies in clinical trials.
Deep dives
The Evolution of Medicine and Personal Motivation
John Leonard reflects on his 30-year journey in pharmaceutical research, emphasizing how his experiences, particularly during the AIDS epidemic, have shaped his approach to drug development. He highlights the groundbreaking impact of HIV protease inhibitors in the mid-90s, which drastically reduced AIDS-related mortality in the U.S. Leonard shares how this history fuels his passion for bringing new medications into practice rather than being directly involved in patient care. His perspective illustrates a commitment to advancing therapeutic options that can fundamentally improve patient lives.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
